WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
www.gsk.com
List of articles in category GlaxoSmithKline
Title
Published Date
US FDA Advisory Committee votes to support effectiveness and safety of GSK's respiratory syncytial virus older adult vaccine candidate
06 March 2023
GSK announces results from 17-year retrospective study on US clinical trial diversity
09 February 2023
VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
28 December 2022
GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
13 December 2022
GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
17 November 2022
GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D
18 October 2022
WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria vaccine
19 September 2022
GSK signs agreement to support pandemic preparedness in Europe
01 August 2022
GSK completes acquisition of Sierra Oncology
04 July 2022
GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
23 June 2022
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
Pfizer invests $43 billion to battle cancer
Research & Development
'Biohybrid' device could restore function in paralysed limbs
Scientists use tardigrade proteins for human health breakthrough
DNA treatment could delay paralysis that strikes nearly all patients with ALS
Scientists reveal a potential new approach to treating liver cancer
Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Engineered bacteria find tumors, then alert the authorities
First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases
Conferences & Events
SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
SAE Media Group's 6th annual 3D Cell Culture Conference
CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
CPHI Excellence in Pharma Award Winners 2022
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
FDA grants Accelerated Approval for Alzheimer's disease treatment
FDA approves new HIV drug for adults with limited treatment options
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
FDA approves first gene therapy to treat adults with Hemophilia B
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
You are here:
Home
GlaxoSmithKline
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19